文献速递病毒性肝炎

奥比他韦/帕利瑞韦/利托那韦联合达沙布韦治疗及可变利巴韦林剂量下的肝脏药代动力学与药效学

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
PubMed 文献 · J Infect Dis · 2018-01-01

这项部分随机、开放标签的2期研究纳入初治无肝硬化基因1a型丙型肝炎患者,比较不同利巴韦林方案对肝脏与血浆HCV RNA早期下降的影响。结果显示,治疗前2周内利巴韦林给药与否及剂量均未对血浆或肝脏HCV RNA下降产生明显影响。

要点

  • 基线血浆HCV RNA高于肝脏,且血浆中下降更快。
  • 前2周内利巴韦林给药方案未影响血浆或肝脏HCV RNA下降。
  • 最常见不良事件为细针穿刺相关疼痛。

核心结论

  • 无论利巴韦林剂量如何,合用利巴韦林对治疗前2周血浆或肝脏HCV RNA下降动力学影响极小。

研究设计与样本

  • 部分随机、开放标签的2期研究,纳入初治无肝硬化基因1a型HCV患者,随机1:1进入A组和B组,随后纳入C组。
  • A组前2周不用利巴韦林,之后按体重给药;B组全12周按体重给利巴韦林;C组全12周每日一次低剂量利巴韦林600 mg。
  • 所有患者接受奥比他韦/帕利瑞韦/利托那韦联合达沙布韦治疗12周,采用细针穿刺(FNA)测定肝内HCV RNA下降。

主要发现

  • 基线血浆HCV RNA高于肝脏,且血浆中下降更迅速。
  • 前2周内利巴韦林给药未影响血浆或肝脏HCV RNA中位下降。
  • 肝脏与血浆药物浓度随时间变化较大。
  • 最常见不良事件为FNA相关疼痛。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unknown whether ribavirin (RBV) coadministration modifies the early rate of decline of hepatitis C virus (HCV) RNA in the liver versus plasma compartments, specifically. METHODS: This partially randomized, open-label, phase 2 study enrolled treatment-naive, noncirrhotic patients with HCV genotype 1a. Patients were randomized 1:1 into Arms A and B, and then enrolled in Arm C. Patients received ombitasvir/paritaprevir/ritonavir plus dasabuvir for 12 weeks with either: no RBV for the first 2 weeks followed by weight-based dosing thereafter (Arm A), weight-based RBV for all 12 weeks (Arm B), or low-dose RBV (600 mg) once daily for all 12 weeks. Fine needle aspiration (FNA) was used to determine HCV RNA decline within liver. RESULTS: Baseline HCV RNA was higher and declined more rapidly in plasma than liver; however, RBV dosing did not impact either median plasma or liver HCV RNA decline during the first 2 weeks of treatment. Liver-to-plasma drug concentrations were variable over time. The most common adverse event was pain associated with FNA. CONCLUSIONS: Coadministration of RBV had minimal visible impact on the plasma or liver kinetics of HCV RNA decline during the first 2 weeks of treatment, regardless of RBV dosing.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Talal AH, Dumas EO, Bauer B, et al. Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage. J Infect Dis. 2018. PMID: 29228392. doi:10.1093/infdis/jix495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。